Hsueh, Shih-ChangParekh, PathikBatsaikhan, BuyandelgerVargesson, NeilTweedie, DavidLuo, WeimingPatel, Chirag N.Liu, DongMcDevitt, Ross A.Baig, Abdul MannanKim, Yu KyungKim, SunHwang, InhoKim, JuwanLee, Mee YounCarta, Anna R.Selman, Warren R.Hoffer, Barry J.Kim, Dong SeokGreig, Nigel H2025-06-262025-06-262025Hsueh, S-C, Parekh, P, Batsaikhan, B, Vargesson, N, Tweedie, D, Luo, W, Patel, C N, Liu, D, McDevitt, R A, Baig, A M, Kim, Y K, Kim, S, Hwang, I, Kim, J, Lee, M Y, Carta, A R, Selman, W R, Hoffer, B J, Kim, D S & Greig, N H 2025, 'Targeting neuroinflammation : 3-Monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration', Journal of Biomedical Science, vol. 32, 57. https://doi.org/10.1186/s12929-025-01150-w1423-0127ORCID: /0000-0001-8027-114X/work/186968774https://hdl.handle.net/2164/25625All authors thank Dr. Michael T. Scerba (Intramural Research Program, National Institute on Aging, NIH, USA) for quantifying the concentration of 3-MP following its nanoformulation.295315237engSubstantive connection via an eligible employment contractSDG 3 - Good Health and Well-beingNeuroinflammationImmunomodulatory imide drugs (IMiDs)MeurodegenerationMicrogliaTetratogenicityPomalidomidecereblonSplat like transcription factorSALL4Traumatic brain injuryR Medicine (General)Supplementary DataDASR1Journal article10.1186/s12929-025-01150-w32